From de novo mutations to personalized therapeutic interventions in autism

Annual Review of Medicine

Volumn 66, Issue , 2015, Pages 487-507

  Brandler, William M ^a,b   Sebat, Jonathan ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

autism spectrum disorder; clinical trials; copy number variation; fragile X syndrome; genomics; metabolic disorders; mouse models; Rett syndrome; whole genome sequencing

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CENTRAL STIMULANT AGENT; NEUROLEPTIC AGENT;

ARTICLE; AUTISM; COPY NUMBER VARIATION; DE NOVO MUTATION; DISRUPTIVE BEHAVIOR; DNA SEQUENCE; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC RISK; GENOTYPE; HUMAN; INBORN ERROR OF METABOLISM; MICROARRAY ANALYSIS; NONHUMAN; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; SPONTANEOUS MUTATION; CHILD DEVELOPMENT DISORDERS, PERVASIVE; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; MUTATION; PERSONALIZED MEDICINE; PROCEDURES;

CHILD DEVELOPMENT DISORDERS, PERVASIVE; DNA COPY NUMBER VARIATIONS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOTYPE; HUMANS; MUTATION; PHENOTYPE; PRECISION MEDICINE; SEQUENCE ANALYSIS, DNA;

EID: 84921367138     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-091113-024550     Document Type: Article

References (110)

1. Geschwind DH. 2009. Advances in autism. Annu. Rev. Med. 60:367-80
2. Power RA, Kyaga S, Uher R, et al. 2013. Fecundity of patients with schizophrenia, autism, bipolar disorder, depression, anorexia nervosa, or substance abuse versus their unaffected siblings. JAMA Psychiatry 70:22-30
3. Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators. 2012. Prevalence of autism spectrum disorders-Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. MMWR Surveill. Summ. 61:1-19
4. Ganz ML. 2007. The lifetime distribution of the incremental societal costs of autism. Arch. Pediatr. Adolesc. Med. 161:343-49
5. Bailey A, Lecouteur A, Gottesman I, et al. 1995. Autism as a strongly genetic disorder-evidence from a British twin study. Psychol. Med. 25:63-77
6. Ronald A, Hoekstra RA. 2011. Autism spectrum disorders and autistic traits: a decade of new twin studies. Am. J. Med. Genet. B Neuropsychiatr. Genet. 156B:255-74
7. Hallmayer J, Cleveland S, Torres A, et al. 2011. Genetic heritability and shared environmental factors among twin pairs with autism. Arch. Gen. Psychiatry 68:1095-102
8. RonemusM, Iossifov I, Levy D, Wigler M. 2014. The role of de novomutations in the genetics of autism spectrum disorders. Nat. Rev. Genet. 15:133-41
9. Freitag CM. 2007. The genetics of autistic disorders and its clinical relevance: a review of the literature. Mol. Psychiatry 12:2-22
10. Anney R, Klei L, Pinto D, et al. 2012. Individual common variants exert weak effects on the risk for autism spectrum disorders. Hum. Mol. Genet. 21:4781-92
11. Anney R, Klei L, Pinto D, et al. 2010. A genome-wide scan for common alleles affecting risk for autism. Hum. Mol. Genet. 19:4072-82
12. WangK, ZhangH, MaD, et al. 2009.Commongenetic variants on 5p14.1 associatewith autism spectrum disorders. Nature 459:528-33
13. Weiss LA, Arking DE, Daly MJ, et al. 2009. A genome-wide linkage and association scan reveals novel loci for autism. Nature 461:802-8
14. Gaugler T, Klei L, Sanders SJ, et al. 2014. Most genetic risk for autism resides with common variation. Nat. Genet. 46:881-85
15. Cross-Disorder Group of the Psychiatric Genomics Consortium, Lee SH, Ripke S, et al. 2013. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat. Genet. 45:984-94
16. SchizophreniaWorking Group of the PsychiatricGenomics Consortium. 2014. Biological insights from 108 schizophrenia-Associated genetic loci. Nature 511:421-27
17. Sebat J, Lakshmi B, Malhotra D, et al. 2007. Strong association of de novo copy number mutations with autism. Science 316:445-49
18. Reichenberg A, Gross R, WeiserM, et al. 2006. Advancing paternal age and autism. Arch. Gen. Psychiatry 63:1026-32
19. Crow JF. 2000. The origins, patterns and implications of human spontaneous mutation. Nat. Rev. Genet. 1:40-47
20. Sebat J, Lakshmi B, Troge J, et al. 2004. Large-scale copy number polymorphism in the human genome. Science 305:525-28
21. Iafrate AJ, Feuk L, Rivera MN, et al. 2004. Detection of large-scale variation in the human genome. Nat. Genet. 36:949-51
22. Sanders SJ, Ercan-Sencicek AG, Hus V, et al. 2011. Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. Neuron 70:863-85
23. Pinto D, Delaby E, Merico D, et al. 2014. Convergence of genes and cellular pathways dysregulated in autism spectrum disorders. Am. J. Hum. Genet. 94:677-94
24. Levy D, Ronemus M, Yamrom B, et al. 2011. Rare de novo and transmitted copy-number variation in autistic spectrum disorders. Neuron 70:886-97
25. Kumar RA, KaraMohamed S, Sudi J, et al. 2008. Recurrent 16p11.2 microdeletions in autism. Hum. Mol. Genet. 17:628-38
26. Christian SL, Brune CW, Sudi J, et al. 2008. Novel submicroscopic chromosomal abnormalities detected in autism spectrum disorder. Biol. Psychiatry 63:1111-17
27. Itsara A, Wu H, Smith JD, et al. 2010. De novo rates and selection of large copy number variation. Genome Res. 20:1469-81
28. Gilman SR, Iossifov I, Levy D, et al. 2011. Rare de novo variants associated with autism implicate a large functional network of genes involved in formation and function of synapses. Neuron 70:898-907
29. Sanders SJ, Ercan-Sencicek AG, Hus V, et al. 2011. Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. Neuron 70:863-85
30. O'Roak BJ, Deriziotis P, Lee C, et al. 2011. Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations. Nat. Genet. 43:585-89
31. Nord AS, RoebW, Dickel DE, et al. 2011. Reduced transcript expression of genes affected by inherited and de novo CNVs in autism. Eur. J. Hum. Genet. 19:727-31
32. Neale BM, Kou Y, Liu L, et al. 2012. Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature 485:242-45
33. Sanders SJ, Murtha MT, Gupta AR, et al. 2012. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature 485:237-41
34. Iossifov I, Ronemus M, Levy D, et al. 2012. De novo gene disruptions in children on the autistic spectrum. Neuron 74:285-99
35. Malhotra D, Sebat J. 2012. CNVs: harbingers of a rare variant revolution in psychiatric genetics. Cell 148:1223-41
36. O'Roak BJ, Vives L, Girirajan S, et al. 2012. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature 485:246-50
37. Bernstein BE, Birney E, Dunham I, et al. 2012. An integrated encyclopedia of DNA elements in the human genome. Nature 489:57-74
38. Michaelson JJ, Shi Y, Gujral M, et al. 2012. Whole-genome sequencing in autism identifies hot spots for de novo germline mutation. Cell 151:1431-42
39. Jiang YH, Yuen RK, Jin X, et al. 2013. Detection of clinically relevant genetic variants in autism spectrum disorder by whole-genome sequencing. Am. J. Hum. Genet. 93:249-63
40. Kong A, Frigge ML, Masson G, et al. 2012. Rate of de novo mutations and the importance of father's age to disease risk. Nature 488:471-75
41. Goldstein DB, Allen A, Keebler J, et al. 2013. Sequencing studies in human genetics: design and interpretation. Nat. Rev. Genet. 14:460-70
42. MacArthur DG, Balasubramanian S, Frankish A, et al. 2012. A systematic survey of loss-of-function variants in human protein-coding genes. Science 335:823-28
43. Tabor HK, Cho MK. 2007. Ethical implications of array comparative genomic hybridization in complex phenotypes: points to consider in research. Genet. Med. 9:626-31
44. Kearney HM, Thorland EC, Brown KK, et al. 2011. American College of Medical Genetics standards and guidelines for interpretation and reporting of postnatal constitutional copy number variants. Genet. Med. 13:680-85
45. Bernier R, Golzio C, Xiong B, et al. 2014. Disruptive CHD8 mutations define a subtype of autism early in development. Cell 158:263-76
46. Mefford HC, Sharp AJ, Baker C, et al. 2008. Recurrent rearrangements of chromosome 1q21.1 and variable pediatric phenotypes. N. Engl. J. Med. 359:1685-99
47. Cook EH Jr, Lindgren V, Leventhal BL, et al. 1997. Autism or atypical autism in maternally but not paternally derived proximal 15q duplication. Am. J. Hum. Genet. 60:928-34
48. Burnside RD, Pasion R, Mikhail FM, et al. 2011. Microdeletion/microduplication of proximal 15q11.2 between BP1 and BP2: a susceptibility region for neurological dysfunction including developmental and language delay. Hum. Genet. 130:517-28
49. Weiss LA, Shen YP, Korn JM, et al. 2008. Association between microdeletion and microduplication at 16p11.2 and autism. N. Engl. J. Med. 358:667-75
50. Sebat J, Levy DL, McCarthy SE. 2009. Rare structural variants in schizophrenia: one disorder, multiple mutations; one mutation, multiple disorders. Trends Genet. 25:528-35
51. McCarthy SE, Makarov V, Kirov G, et al. 2009. Microduplications of 16p11.2 are associated with schizophrenia. Nat. Genet. 41:1223-27
52. KirovG, Pocklington AJ, Holmans P, et al. 2012. De novoCNVanalysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol. Psychiatry 17:142-53
53. Stefansson H, Meyer-Lindenberg A, Steinberg S, et al. 2014. CNVs conferring risk of autism or schizophrenia affect cognition in controls. Nature 505:361-66
54. Shinawi M, Liu P, Kang SH, et al. 2010. Recurrent reciprocal 16p11.2 rearrangements associated with global developmental delay, behavioural problems, dysmorphism, epilepsy, and abnormal head size. J. Med. Genet. 47:332-41
55. Moreno-De-Luca A, Myers SM, Challman TD, et al. 2013. Developmental brain dysfunction: revival and expansion of old concepts based on new genetic evidence. Lancet Neurol. 12:406-14
56. Deleted in proof
57. Stefansson H, Rujescu D, Cichon S, et al. 2008. Large recurrent microdeletions associated with schizophrenia. Nature 455:232-36
58. Fombonne E. 2009. Epidemiology of pervasive developmental disorders. Pediatr. Res. 65:591-98
59. Werling DM, Geschwind DH. 2013. Understanding sex bias in autism spectrum disorder. Proc. Natl. Acad. Sci. USA 110:4868-69
60. Zhao X, Leotta A, Kustanovich V, et al. 2007. A unified genetic theory for sporadic and inherited autism. Proc. Natl. Acad. Sci. USA 104:12831-36
61. Ozonoff S, Young GS, Carter A, et al. 2011. Recurrence risk for autism spectrum disorders: a Baby Siblings Research Consortium study. Pediatrics 128:e488-95
62. Jacquemont S, Coe BP, Hersch M, et al. 2014. A higher mutational burden in females supports a 'female protective model' in neurodevelopmental disorders. Am. J. Hum. Genet. 94:415-25
63. International Schizophrenia Consortium, Purcell SM, Wray NR, et al. 2009. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460:748-52
64. Girirajan S, Rosenfeld JA, Coe BP, et al. 2012. Phenotypic heterogeneity of genomic disorders and rare copy-number variants. N. Engl. J. Med. 367:1321-31
65. Sung M, Fung DS, Cai Y, Ooi YP. 2010. Pharmacological management in children and adolescents with pervasive developmental disorder. Aust. N.Z. J. Psychiatry 44:410-28
66. Sung M, Chin CH, Lim CG, et al. 2014. What's in the pipeline?. Drugs in development for autism spectrum disorder. Neuropsychiatr. Dis. Treat. 10:371-81
67. Bickel H, Gerrard J, Hickmans EM. 1953. Influence of phenylalanine intake on phenylketonuria. Lancet 265:812-13
68. Novarino G, El-Fishawy P, Kayserili H, et al. 2012. Mutations in BCKD-kinase lead to a potentially treatable form of autism with epilepsy. Science 338:394-97
69. Harris RA, Joshi M, Jeoung NH, Obayashi M. 2005. Overview of the molecular and biochemical basis of branched-chain amino acid catabolism. J. Nutr. 135:1527S-30S
70. Celestino-Soper PB, Shaw CA, Sanders SJ, et al. 2011. Use of array CGH to detect exonic copy number variants throughout the genome in autism families detects a novel deletion in TMLHE. Hum. Mol. Genet. 20:4360-70
71. Celestino-Soper PB, Violante S, Crawford EL, et al. 2012. A common X-linked inborn error of carnitine biosynthesis may be a risk factor for nondysmorphic autism. Proc. Natl. Acad. Sci. USA 109:7974-81
72. Geier DA, Kern JK, Davis G, et al. 2011. A prospective double-blind, randomized clinical trial of levocarnitine to treat autism spectrum disorders. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 17:PI15-23
73. Tierney E, Nwokoro NA, Porter FD, et al. 2001. Behavior phenotype in the RSH/Smith-Lemli-Opitz syndrome. Am. J. Med. Genet. 98:191-200
74. Sikora DM, Pettit-Kekel K, Penfield J, et al. 2006. The near universal presence of autism spectrum disorders in children with Smith-Lemli-Opitz syndrome. Am. J. Med. Genet. A 140:1511-18
75. Sikora DM, Ruggiero M, Petit-Kekel K, et al. 2004. Cholesterol supplementation does not improve developmental progress in Smith-Lemli-Opitz syndrome. J. Pediatr. 144:783-91
76. Aneja A, Tierney E. 2008. Autism: the role of cholesterol in treatment. Int. Rev. Psychiatr. 20:165-70
77. Amir RE, Van den Veyver IB, Wan M, et al. 1999. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 23:185-88
78. Guy J, Gan J, Selfridge J, et al. 2007. Reversal of neurological defects in a mousemodel of Rett syndrome. Science 315:1143-47
79. Buchovecky CM, Turley SD, Brown HM, et al. 2013. A suppressor screen in Mecp2 mutant mice implicates cholesterol metabolism in Rett syndrome. Nat. Genet. 45:1013-20
80. GhoshA, MichalonA, Lindemann L, et al. 2013. Drug discovery for autism spectrum disorder: challenges and opportunities. Nat. Rev. Drug Discov. 12:777-90
81. Huber KM, Gallagher SM, Warren ST, Bear MF. 2002. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc. Natl. Acad. Sci. USA 99:7746-50
82. Dolen G, Osterweil E, Rao BS, et al. 2007. Correction of fragile X syndrome in mice. Neuron 56:955-62
83. Auerbach BD, Osterweil EK, Bear MF. 2011. Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature 480:63-68
84. Henderson C, Wijetunge L, Kinoshita MN, et al. 2012. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci. Transl. Med. 4:152ra28
85. Berry-Kravis EM, Hessl D, Rathmell B, et al. 2012. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci. Transl. Med. 4:152ra27
86. Delahunty C, Walton-Bowen K, Kuriyams N, et al 2013. Randomized, Controlled, Phase 2 Trial of STX209 (Arbaclofen) for Social Function in ASD. https://aap.confex.com/aap/2013/webprogrampress/Paper22373.html
87. Jacquemont S, Curie A, des Portes V, et al. 2011. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci. Transl. Med. 3:64ra1
88. Braat S, Kooy RF. 2014. Fragile X syndrome neurobiology translates into rational therapy. Drug Discov. Today 19:510-19
89. Kremer EJ, Pritchard M, Lynch M, et al. 1991. Mapping of DNA instability at the fragile X to a trinucleotide repeat sequence p(CCG)n. Science 252:1711-14
90. Constantino JN, Todd RD. 2003. Autistic traits in the general population: a twin study. Arch. Gen. Psychiatry 60:524-30
91. Fischbach GD, Lord C. 2010. The Simons Simplex Collection: a resource for identification of autism genetic risk factors. Neuron 68:192-95
92. O'Roak BJ, Vives L, Fu W, et al. 2012. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. Science 338:1619-22
93. Deleted in proof
94. de Ligt J, WillemsenMH, van Bon BW, et al. 2012. Diagnostic exome sequencing in persons with severe intellectual disability. N. Engl. J. Med. 367:1921-29
95. Rauch A, Wieczorek D, Graf E, et al. 2012. Range of genetic mutations associated with severe nonsyndromic sporadic intellectual disability: an exome sequencing study. Lancet 380:1674-82
96. Gilissen C, Hehir-Kwa JY, ThungDT, et al. 2014. Genome sequencing identifies major causes of severe intellectual disability. Nature 511:344-47
97. Tabuchi K, Blundell J, Etherton MR, et al. 2007. A neuroligin-3 mutation implicated in autism increases inhibitory synaptic transmission in mice. Science 318:71-76
98. Hamdan FF, Piton A, Gauthier J, et al. 2009. De novo STXBP1 mutations in mental retardation and nonsyndromic epilepsy. Ann. Neurol. 65:748-53
99. Milh M, Villeneuve N, Chouchane M, et al. 2011. Epileptic and nonepileptic features in patients with early onset epileptic encephalopathy and STXBP1 mutations. Epilepsia 52:1828-34
100. Coe BP, Witherspoon K, Rosenfeld JA, et al. 2014. Refining analyses of copy number variation identifies specific genes associated with developmental delay. Nat. Genet. 46:1063-71
101. Hamdan FF, Daoud H, Piton A, et al. 2011. De novo SYNGAP1mutations in nonsyndromic intellectual disability and autism. Biol. Psychiatry 69:898-901
102. Golzio C, Willer J, TalkowskiME, et al. 2012. KCTD13 is a major driver of mirrored neuroanatomical phenotypes of the 16p11.2 copy number variant. Nature 485:363-67
103. Docker D, Schubach M, Menzel M, et al. 2014. Further delineation of the SATB2 phenotype. Eur. J. Hum. Genet. 22:1034-39
104. Halgren C, Kjaergaard S, Bak M, et al. 2012. Corpus callosum abnormalities, intellectual disability, speech impairment, and autism in patients with haploinsufficiency of ARID1B. Clin. Genet. 82:248-55
105. Hoyer J, Ekici AB, Endele S, et al. 2012. Haploinsufficiency of ARID1B, a member of the SWI/SNF-A chromatin-remodeling complex, is a frequent cause of intellectual disability. Am. J. Hum. Genet. 90:565-72
106. Deleted in proof
107. Tatton-Brown K, Seal S, Ruark E, et al. 2014. Mutations in the DNAmethyltransferase gene DNMT3A cause an overgrowth syndrome with intellectual disability. Nat. Genet. 46:385-88
108. Kuechler A, Zink AM, Wieland T, et al. 2014. Loss-of-function variants of SETD5 cause intellectual disability and the core phenotype of microdeletion 3p25.3 syndrome. Eur. J. Hum. Genet. In press
109. Grozeva D, Carss K, Spasic-Boskovic O, et al. 2014. De novo loss-of-function mutations in SETD5, encoding amethyltransferase in a 3p25 microdeletion syndrome critical region, cause intellectual disability. Am. J. Hum. Genet. 94:618-24
110. Le Fevre AK, Taylor S, Malek NH, et al. 2013. FOXP1 mutations cause intellectual disability and a recognizable phenotype. Am. J. Med. Genet. A 161A:3166-75